PROF Andreas Strasser

PROF Andreas Strasser Faculty Member uri icon

  • The control of apoptosis in cancer and immune regulation (apoptosis, Bcl-2 family, immunology, leukemia, lymphoma, hemopoietic system, cancer therapies, mouse models)



  • Our laboratory investigates the molecular mechanisms that cause cancer and those that determine the response of malignant tumour cells to diverse anti-cancer agents.

    We have a particular focus on the roles of the different programmed cell death processes (e.g. apoptosis, necroptosis, proptosis) in cancer and the processes that are activated by p53 to suppress tumor development.    



Selected publications




Supervision Statement

  • Dr Strasser and his team are investigating the control of apoptosis, the cell death program essential for development and homeostasis. By using transgenic mice over-expressing the cell death inhibitor Bcl-2 and knock-out mice lacking one of its antagonists, they demonstrated that abnormalities in the control of apoptosis can cause autoimmune disease or cancer and render tumour cells refractory to anti-cancer therapy. Dr Strasser and his co-workers established that mammalian cells have two distinct signalling pathways leading to apoptosis, one triggered by ligation of cell surface "death receptors" and the other by certain developmental cues, cytokine deprivation or stress signals. Using genetically modified mice they could determine signalling mechanisms that are responsible for killing useless or potentially dangerous at the different checkpoints during lymphocyte development. Using biochemical and molecular biology techniques, Dr Strasser and his team discovered novel regulators that are essential for initiation of programmed cell death and showed that they function as sentinels for damage to various vital intra-cellular structures, such as the cytoskeleton. These discoveries have major implications for cancer research, developmental biology and immunology and suggest novel therapeutic strategies for tumours, autoimmunity and degenerative diseases.

    Current research interests include identification of the signalling pathways that mediate developmentally programmed cell death in mammals and those that are responsible for chemotherapy-induced killing of cancer cells, with the goal to develop improved strategies for treatment of cancer and autoimmune diseases.   


Has work location

  • Level: Room:, Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital